AR061015A1 - Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto - Google Patents

Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto

Info

Publication number
AR061015A1
AR061015A1 ARP070102147A ARP070102147A AR061015A1 AR 061015 A1 AR061015 A1 AR 061015A1 AR P070102147 A ARP070102147 A AR P070102147A AR P070102147 A ARP070102147 A AR P070102147A AR 061015 A1 AR061015 A1 AR 061015A1
Authority
AR
Argentina
Prior art keywords
receiver
optionally substituted
composition
compound
group
Prior art date
Application number
ARP070102147A
Other languages
English (en)
Inventor
Derek Cecil Cole
Magda Asselin
Gmbh Co Kg Stockhausen
Ji-In Kim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061015A1 publication Critical patent/AR061015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Reivindicacion 1: Un compuesto de formula (1), caracterizado porque X es CO, CH2 o SOm; Y es NR6, NR6CO, O o SOp; m y p son cada uno individualmente 0 o un entero de 1 o 2; R1 y R2 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido o R1 y R2 pueden ser tomados juntos con el átomo al cual ellos están unidos para formar un anillo de 4 a 7 miembros opcionalmente sustituido que contiene uno o dos heteroátomos adicionales seleccionados de N, O o S; R3 es NR7R8 o un grupo arilo o heteroarilo cada grupo opcionalmente sustituido con la condicion de que cuando Y es NR6, O o SOp entonces R3 debe ser un grupo arilo o heteroarilo cada grupo opcionalmente sustituido; R4 y R5 son cada uno independientemente H, halogeno, OR9 o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo, o heteroarilo cada uno opcionalmente sustituido; R6 y R9 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido; y R7 y R8 son tomados juntos con el átomo al cual ellos están unidos para formar un sistema de anillo de 9- a 11- miembros opcionalmente sustituido bicíclico o tricíclico fusionado que contiene opcionalmente uno a tres heteroátomos adicionales seleccionados de N, O o S; o un estereoisomero de éstos o una sal farmacéuticamente aceptable de éstos.
ARP070102147A 2006-05-19 2007-05-18 Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto AR061015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80190506P 2006-05-19 2006-05-19

Publications (1)

Publication Number Publication Date
AR061015A1 true AR061015A1 (es) 2008-07-30

Family

ID=38616614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102147A AR061015A1 (es) 2006-05-19 2007-05-18 Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto

Country Status (12)

Country Link
US (1) US7842715B2 (es)
EP (1) EP2027086B1 (es)
JP (1) JP2009537542A (es)
CN (1) CN101432261A (es)
AR (1) AR061015A1 (es)
AT (1) ATE533744T1 (es)
AU (1) AU2007254232A1 (es)
CA (1) CA2649913A1 (es)
MX (1) MX2008014743A (es)
PE (1) PE20080371A1 (es)
TW (1) TW200811165A (es)
WO (1) WO2007136668A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709612A2 (pt) * 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US20100063047A1 (en) * 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
JP2013545737A (ja) * 2010-11-01 2013-12-26 ニューロチューン・アクチエンゲゼルシャフト 新規ニューロトリプシン阻害剤
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102784146A (zh) * 2011-05-19 2012-11-21 复旦大学 N-苯基喹唑啉-4-胺类衍生物的药用用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US5656642A (en) 1993-04-07 1997-08-12 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing piperidine derivative as active ingredient
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
DE69819539T2 (de) * 1997-05-01 2004-09-30 Eli Lilly And Co., Indianapolis Antithrombotische mittel
JP2001526178A (ja) 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
KR100622613B1 (ko) * 1997-11-18 2006-09-11 데이진 화-마 가부시키가이샤 시클릭 아민 유도체 및 그 약제로서의 용도
KR20010070997A (ko) 1998-07-20 2001-07-28 플레믹 크리스티안 비페닐 유도체
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
AU2001247906A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles and indazoles
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
WO2003040402A2 (en) 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SI1499311T1 (sl) * 2002-03-29 2010-03-31 Novartis Vaccines & Diagnostic Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze
US20050182256A1 (en) 2002-04-08 2005-08-18 Duggan Mark E. Inhibitors of akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
WO2004052858A2 (en) 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake
CA2519063C (en) 2003-03-14 2011-05-10 Avidex Limited Immunomodulating heterocyclic compounds
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
MXPA06013042A (es) * 2004-05-14 2007-02-12 Millennium Pharm Inc Compuestos y m??todos para inhibir la progresion mit??tica.
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
CN1989115B (zh) 2004-07-26 2012-03-21 伊莱利利公司 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途
ES2534605T3 (es) 2004-08-23 2015-04-24 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
KR20070108881A (ko) * 2005-01-27 2007-11-13 교와 핫꼬 고교 가부시끼가이샤 Ｉｇｆ－１ｒ 저해제
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
PE20071156A1 (es) 2006-03-20 2008-01-31 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
US20070270440A1 (en) 2007-11-22
AU2007254232A1 (en) 2007-11-29
CN101432261A (zh) 2009-05-13
JP2009537542A (ja) 2009-10-29
CA2649913A1 (en) 2007-11-29
EP2027086B1 (en) 2011-11-16
WO2007136668A2 (en) 2007-11-29
WO2007136668A9 (en) 2008-03-27
WO2007136668A3 (en) 2008-01-24
EP2027086A2 (en) 2009-02-25
TW200811165A (en) 2008-03-01
PE20080371A1 (es) 2008-04-09
US7842715B2 (en) 2010-11-30
MX2008014743A (es) 2008-12-01
ATE533744T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
SV2017005384A (es) Compuestos aminopirimidinilo
UY29301A1 (es) Derivados amida
AR078786A1 (es) Derivados de la cromenona
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR046964A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR087309A1 (es) Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
AR100530A1 (es) Compuestos antihelmínticos
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa

Legal Events

Date Code Title Description
FB Suspension of granting procedure